Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Ceran, Ceyhan ^a   Cokol, Murat ^b   Cingoz, Sultan ^c   Tasan, Ipek ^a   Ozturk, Mehmet ^a   Yagci, Tamer ^a,d  

^a BILKENT UNIVERSITY   (Turkey)

^b SABANCI UNIVERSITY   (Turkey)

^c DOKUZ EYLUL UNIVERSITY   (Turkey)

^d GEBZE TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Antagonism; Breast Cancer; Epitope Mapping; ERBB2; Growth Inhibition; HER2; Monoclonal Antibodies; Synergy; TNF

Indexed keywords

AEPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; ANTINEOPLASTIC AGENT; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCLONAL ANTIBODY; PROTEIN KINASE B; PROTEIN VARIANT; RECOMBINANT EPIDERMAL GROWTH FACTOR RECEPTOR 2; RECOMBINANT PROTEIN; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; BIOACCUMULATION; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN BT 474; CELL STRAIN MDA MB 361; CELL STRAIN SK BR 3; CELL STRAIN T47D; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENE AMPLIFICATION; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PLASMID; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; DRUG SYNERGISM; EPITOPES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MCF-7 CELLS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84866896044     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-450     Document Type: Article

References (50)

1. National Cancer Institute Probability of breast cancer in American women. http://www.cancer.gov/cancertopics/factsheet/Detection/probability-breast-cancer, National Cancer Institute.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DMP. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917. 10.1002/ijc.25516, 21351269.
3. National Cancer Institute Breast cancer. http://www.cancer.gov/cancertopics/types/breast, National Cancer Institute.
4. Slamon D, Godolphin W, Jones L, Holt J, Wong S, Keith D, Levin W, Stuart S, Udove J, Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712. 10.1126/science.2470152, 2470152.
5. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985, 229:974-976. 10.1126/science.2992089, 2992089.
6. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009, 9:463-475. 10.1038/nrc2656, 19536107.
7. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. New Eng J Med 2007, 357:39-51. 10.1056/NEJMra043186, 17611206.
8. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene 2007, 26:3637-3643. 10.1038/sj.onc.1210379, 17530017.
9. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, Arteaga CL. Human breast cancer cells selected for resistance to Trastuzumab in vivo overexpress Epidermal Growth Factor Receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007, 13:4909-4919. 10.1158/1078-0432.CCR-07-0701, 17699871.
10. Valabrega G, Montemurro F, Sarotto I, Petrelli A, Rubini P, Tacchetti C, Aglietta M, Comoglio PM, Giordano S. TGFα expression impairs Trastuzumab-induced HER2 downregulation. Oncogene 2005, 24:3002-3010. 10.1038/sj.onc.1208478, 15735715.
11. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-i receptor signaling and resistance to Trastuzumab (Herceptin). J Natl Cancer Inst 2001, 93:1852-7. 10.1093/jnci/93.24.1852, 11752009.
12. Nahta R, Yuan LXH, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-i receptor/human epidermal growth factor receptor 2 heterodimerization contributes to Trastuzumab resistance of breast cancer cells. Cancer Res 2005, 65:11118-11128. 10.1158/0008-5472.CAN-04-3841, 16322262.
13. Nagy P, Friedländer E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin TL. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005, 65:473-482.
14. Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, Massuti B, Cortes-Funes H, Lloveras B. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 2000, 6:2356-2362.
15. Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA, Younger J, Panasci LL, Millard F, Duggan DB, Norton L, Henderson IC. Circulating HER-2/erbB-2/c- neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 2001, 7:2703-2711.
16. Chan CT, Metz MZ, Kane SE. Differential sensitivities of Trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3 K) and epidermal growth factor receptor (EGFR) kinase inhibitors. Breast Cancer Res Treat 2005, 91:187-201. 10.1007/s10549-004-7715-1, 15868447.
17. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by Trastuzumab, and loss of PTEN predicts Trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127. 10.1016/j.ccr.2004.06.022, 15324695.
18. Kute T, Lack CM, Willingham M, Bishwokama B, Williams H, Barrett K, Mitchell T, Vaughn JP. Development of Herceptin resistance in breast cancer cells. Cytometry Part A 2004, 57A:86-93.
19. Gu L, Lau SK, Loera S, Somlo G, Kane SE. Protein Kinase A activation confers resistance to Trastuzumab in human breast cancer cell lines. Clin Cancer Res 2009, 15:7196-7206. 10.1158/1078-0432.CCR-09-0585, 2787631, 19920112.
20. O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ. Activated Phosphoinositide 3-Kinase/AKT signaling confers resistance to Trastuzumab but not Lapatinib. Mol Cancer Ther 2010, 9:1489-1502. 10.1158/1535-7163.MCT-09-1171, 20501798.
21. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, Leahy DJ. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421:756-760. 10.1038/nature01392, 12610629.
22. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002, 2:127-137. 10.1016/S1535-6108(02)00097-1, 12204533.
23. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-Pertuzumab complex. Cancer Cell 2004, 5:317-328. 10.1016/S1535-6108(04)00083-2, 15093539.
24. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies Trastuzumab and Pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004, 64:2343-2346. 10.1158/0008-5472.CAN-03-3856, 15059883.
25. Mumcuoglu M, Bagislar S, Yuzugullu H, Alotaibi H, Senturk S, Telkoparan P, Gur-Dedeoglu B, Cingoz B, Bozkurt B, Tazebay UH, Yulug IG, Akcali CK, Ozturk M. The ability to generate senescent progeny as a mechanism underlying breast cancer cell heterogeneity. Plos One 2010, 5:e11288. 10.1371/journal.pone.0011288, 2891998, 20585577.
26. Senturk S, Mumcuoglu M, Gursoy-Yuzugullu O, Cingoz B, Akcali KC, Ozturk M. Transforming growth factor-beta induces senescence in hepatocellular carcinoma cells and inhibits tumor growth. Hepatology 2010, 52:966-974. 10.1002/hep.23769, 20583212.
27. Shaffer LG, Slovak ML, Campbell LJ. ISCN 2009: An International System for Human Cytogenetic Nomenclature 2009, Basel, Switzerland: S. Karger Publishers.
28. Oztas E, Avci ME, Ozcan A, Sayan AE, Tulchinsky E, Yagci T. Novel monoclonal antibodies detect Smad-interacting protein 1 (SIP1) in the cytoplasm of human cells from multiple tumor tissue arrays. Exp Mol Pathol 2010, 89:182-189. 10.1016/j.yexmp.2010.05.010, 20515682.
29. Wang CX, Koay DC, Edwards A, Lu Z, Mor G, Ocal IT, DiGiovanna MP. In vitro and in vivo effects of combination of Trastuzumab (Herceptin) and Tamoxifen in breast cancer. Breast Cancer Res Treat 2005, 92:251-263. 10.1007/s10549-005-3375-z, 16155796.
30. Zhu H, Zhang G, Wang Y, Xu N, He S, Zhang W, Chen M, Liu M, Quan L, Bai J, Xu N. Inhibition of ErbB2 by Herceptin reduces survivin expression via the ErbB2-beta-catenin/TCF4-survivin pathway in ErbB2-overexpressed breast cancer cells. Cancer Sci 2010, 101:1156-1162. 10.1111/j.1349-7006.2010.01528.x, 20331626.
31. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM. Differential responses of human tumor cell lines to anti-p185Her2 monoclonal antibodies. Cancer Immunol Immunother 1993, 37:255-263. 10.1007/BF01518520, 8102322.
32. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protocols 2006, 1:1112-1116.
33. Bliss C. The toxicity of poisons applied jointly. Ann Appl Biol 1939, 26:585-615.
34. Cokol M, Chua HN, Tasan M, Mutlu B, Weinstein ZB, Suzuki Y, Nergiz ME, Costanzo M, Baryshnikova A, Giaever G, Nislow C, Myers CL, Andrews BJ, Boone C, Roth FP. Systematic exploration of synergistic drug pairs. Mol Syst Biol 2011, 7:1-9.
35. Ozturk N, Erdal E, Mumcuoglu M, Akcali KC, Yalcin O, Senturk S, Arslan-Ergul A, Gur B, Yulug I, Cetin-Atalay R, Yakicier C, Yagci T, Tez M, Ozturk M. Reprogramming of replicative senescence in hepatocellular carcinoma-derived cells. Proc Natl Acad Sci USA 2006, 103:2178-2183. 10.1073/pnas.0510877103, 1413736, 16461895.
36. Gursoy-Yuzugullu O, Yuzugullu H, Yilmaz M, Ozturk M. Aflatoxin genotoxicity is associated with a defective DNA damage response bypassing p53 activation. Liver Int 2011, 31:561-571. 10.1111/j.1478-3231.2011.02474.x, 21382167.
37. Kallioniemi OP, Kallioniemi A, Kurisu W, Thor A, Chen LC, Smith HS, Waldman FM, Pinkel D, Gray JW. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 1992, 89:5321-5325. 10.1073/pnas.89.12.5321, 49283, 1351679.
38. Rusnak D, Alligood K, Mullin R, Spehar G, Arenas-Elliott C, Martin A, Degenhardt Y, Rudolph S, Haws TJ, Hudson-Curtis B, Gilmer T. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb®, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif 2007, 40:580-594. 10.1111/j.1365-2184.2007.00455.x, 17635524.
39. Hsu C, Huang CL, Hsu HC, Lee PH, Wang SJ, Cheng AL. HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity. Cancer 2002, 94:415-420. 10.1002/cncr.10180, 11900227.
40. Hudziak RM, Lewis GD, Shalaby MR, Eessalu TE, Aggarwal BB, Ullrich A, Shepard HM. Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor a in NIH 3T3 cells. Proc Natl Acad Sci USA 1988, 85:5102-5106. 10.1073/pnas.85.14.5102, 281696, 2899323.
41. Zhou BP, Hu MCT, Miller SA, Yu Z, Xia W, Lin SY, Hung MC. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kB pathway. J Biol Chem 2000, 275:8027-8031. 10.1074/jbc.275.11.8027, 10713122.
42. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to Tumor Necrosis Factor. Mol Cell Biol 1989, 9:1165-1172. 362707, 2566907.
43. Yakes F, Chinratanalab W, Ritter C, King W, Seelig S, Arteaga C. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002, 62:4132-41.
44. Gijsen M, King P, Perera T, Parker PJ, Harris AL, Larijani B, Kong A. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 Herceptin in breast cancer. PLoS Biology 2010, 8:e1000563. 10.1371/journal.pbio.1000563, 3006345, 21203579.
45. Sakai K, Yokote H, Murakami-Murofushi K, Tamura T, Saijo N, Nishio K. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway. Cancer Sci 2007, 98:1498-503. 10.1111/j.1349-7006.2007.00553.x, 17627612.
46. Guicciardi ME, Gores GJ. Life and death by death receptors. FASEB J 2009, 23:1625-1637. 10.1096/fj.08-111005, 2698650, 19141537.
47. Stacey DW. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol 2003, 15:158-163. 10.1016/S0955-0674(03)00008-5, 12648671.
48. Lee EA, Keutmann MK, Dowling ML, Harris E, Chan G, Kao GD. Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells. Mol Cancer Ther 2004, 3:661-669.
49. Fitzgerald P, Teng M, Chandraratna RA, Heyman RA, Allegretto EA. Retinoic acid receptor alpha expression correlates with retinoid-induced growth inhibition of human breast cancer cells regardless of estrogen receptor status. Cancer Res 1997, 57:2642-2650.
50. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009, 9:361-371. 10.1038/nrc2628, 19343034.